Delcath Systems Inc Stock Prediction
AI-powered sentiment analysis and prediction trends for DCTH, updated each market day.
DCTH AI Sentiment
AI sees no strong directional signal for Delcath Systems Inc stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Delcath Systems Inc
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Sector
Exchange
Market Cap
$340,411,042
Cap Tier
Employees
156
Headquarters
QUEENSBURY, NY
Listed Since
Oct. 19, 2000
Website
DCTH Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
DCTH Volatility
Delcath Systems Inc has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
